Global Med Technologies(R), Inc. Signs Five-Year $1.2 Million Contract With Prestigious City of Hope National Medical Center City of Hope Selects SafeTrace(R) and SafeTrace Tx(R) DENVER, Dec. 9 /PRNewswire-FirstCall/ -- Wyndgate Technologies(R), a division of Global Med Technologies(R), Inc. (BULLETIN BOARD: GLOB) ("Global Med" or the "Company"), announced the signing of an agreement for its Vein-to-Vein(R) software, SafeTrace(R) donor management and SafeTrace Tx(R)* advanced transfusion management, with City of Hope National Medical Center. With a potential value of $1.2 million over a five-year period, City of Hope will be the largest user of Wyndgate's Vein-to-Vein software in California. Thomas F. Marcinek, President and COO of Global Med Technologies, Inc., stated, "We are pleased to announce this significant business agreement with City of Hope, a very prestigious organization, which is leading the way in cancer research and providing treatments to so many patients with life-threatening illnesses." Mr. Marcinek added, "Our five-year agreement underscores Wyndgate's commitment to safety and quality in helping facilities, such as City of Hope, manage and track blood products from collection to transfusion, using our Vein-to-Vein software. Wyndgate looks forward to a successful partnership with City of Hope." About City of Hope City of Hope National Medical Center is located northeast of Los Angeles in Duarte, California. City of Hope is one of a few prominent Comprehensive Cancer Centers in the United States as designated by the National Cancer Institute (NCI). More than 300 physicians and scientists and over 2,500 employees work at City of Hope to find the causes of and cures for cancer and other life-threatening diseases, including diabetes and HIV/AIDS. For more information about City of Hope, visit its website at http://www.cityofhope.org/. About Global Med Technologies, Inc. Global Med Technologies, Inc. is an e-Health, medical information technology company, providing information management software products and services to the healthcare industry. Its Wyndgate Technologies division is a leading supplier of information management systems to U.S. blood centers and transfusion services. Current clients of Wyndgate's products and services manage more than 3 million units of blood, or over 22% of the U.S. blood supply, each year. Together, SafeTrace Tx and SafeTrace provide Vein-to-Vein tracking from donor collection to patient transfusion. For more information about Global Med's products and services, call 800-WYNDGATE or visit http://www.globalmedtech.com/, http://www.peoplemed.com/ and http://www.wyndgate.com/. This news release may include statements that constitute forward-looking statements, usually containing the words "believe," "estimate," "project," "expects" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this news release. * Patent Pending DATASOURCE: Global Med Technologies, Inc. CONTACT: press, Patti Larson, Senior Director of Marketing Development, +1-916-404-8492, , or investors, Tom Marcinek, President and COO, +1-916-404-8413, , both of Wyndgate Technologies, for Global Med Technologies Web site: http://www.cityofhope.org/ Web site: http://www.wyndgate.com/ Web site: http://www.peoplemed.com/ Web site: http://www.globalmedtech.com/ x

Copyright